Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Locally advanced disease or at high risk for relapse No clinically or radiologically suspected metastases Prior lymphadenectomy required Meets at least 1 of the following criteria for poor prognosis: Gleason score greater than 7 T3 or T4 disease Prostate-specific antigen greater than 20 ng/mL N1 disease PATIENT CHARACTERISTICS: Age Under 80 Performance status ECOG 0-2 Life expectancy More than 10 years Hematopoietic Absolute neutrophil count greater than 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic AST and ALT no greater than 1.5 times upper limit of normal (ULN) Bilirubin no greater than ULN Renal Creatinine less than 1.6 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular No uncontrolled or severe cardiovascular disease No prior thrombosis Pulmonary No prior pulmonary embolus Other No active infection No intolerance to aspirin No other prior malignancy except basal cell skin cancer No physical or psychological condition that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No other concurrent chemotherapy Endocrine therapy No prior hormonal therapy No other concurrent hormonal therapy Radiotherapy Not specified Surgery See Disease Characteristics Other No other concurrent anticancer therapy